|
Synonyms: AV380
Compound class:
Antibody
Comment: Rilogrotug (AV-380; AVEO Pharmaceuticals) is a humanized anti-growth differentiation factor 15 (GDF15) IgG1κ monoclonal antibody. Blocking GDF15 binding to its receptor GFRAL is recognised to induce anti-cachexia efficacy in preclinical models and is proposed as a therapeutic modality to treat cachexia that is caused by over-expression of GDF15 (e.g. cancer-associated cachexia) [1,3].
Data in support of clinical efficacy from a phase 2 trial in patients with cancer-associated cachexia who were administered Pfizer's anti-GDF15 monoclonal, ponsegromab, were published in late 2024 [2]. |
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 13236 | rilogrotug |
| Synonyms |
| AV380 |
| Database Links |
|
| CAS Registry No. | 2894138-72-6 (source: WHO INN record) |
| GtoPdb PubChem SID | 507750298 |
| Search PubMed clinical trials | rilogrotug |
| Search PubMed titles | rilogrotug |
| Search PubMed titles/abstracts | rilogrotug |
